Top

Molecular Neurodegeneration

Published in:

Open Access 01-12-2010 | Research article

Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to Aβ oligomers accumulation

Authors: Antonella Caccamo, Andrea Magrí, Salvatore Oddo

Published in: Molecular Neurodegeneration | Issue 1/2010

Abstract

Background

Transactive response DNA-binding protein 43 (TDP-43) is the pathological protein found in frontotemporal lobar degeneration with ubiquitin positive inclusions and in amyotrophic lateral sclerosis. In diseased tissue, TDP-43 translocates from its physiological nuclear location into the cytoplasm, where it accumulates. Additionally, C-terminal fragments of TDP-43 accumulate in affected brain regions and are sufficient to cause TDP-43 mislocalization and cytoplasmic accumulation in vitro. TDP-43 also accumulates in 30% of Alzheimer disease (AD) cases, a finding that has been highly reproducible. The role of TDP-43 in AD and its relation with Aβ and tau pathology, the two neuropathological hallmarks of AD, remains to be elucidated.

Results

Here we show that levels of TDP-43 and its ~35 kDa C-terminal fragment are significantly increased in the 3×Tg-AD mice, an animal model of AD that develops an age-dependent cognitive decline linked to the accumulation of Aβ and tau. We also report that the levels of TDP-43 and its C-terminal fragment correlate with the levels of soluble Aβ oligomers, which play a key role in AD pathogenesis. Notably, genetically reducing Aβ₄₂ production restores the levels of TDP-43 and its ~35 kDa C-terminal fragment to control levels.

Conclusions

These data suggest a possible relation between Aβ oligomers and TDP-43.

Available only for authorised users

Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, et al: Global prevalence of dementia: a Delphi consensus study. Lancet. 2005, 366: 2112-2117. 10.1016/S0140-6736(05)67889-0.PubMedCrossRef

Artero S, Tierney MC, Touchon J, Ritchie K: Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta psychiatrica Scandinavica. 2003, 107: 390-393. 10.1034/j.1600-0447.2003.00081.x.PubMedCrossRef

Lambon Ralph MA, Patterson K, Graham N, Dawson K, Hodges JR: Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer's disease: a cross-sectional and longitudinal study of 55 cases. Brain. 2003, 126: 2350-2362. 10.1093/brain/awg236.PubMedCrossRef

Welsh KA, Butters N, Hughes JP, Mohs RC, Heyman A: Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Archives of neurology. 1992, 49: 448-452.PubMedCrossRef

Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiological reviews. 2001, 81: 741-766.PubMed

Oddo S: The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med. 2008, 12: 363-373. 10.1111/j.1582-4934.2008.00276.x.PubMedCrossRef

LaFerla FM, Green KN, Oddo S: Intracellular amyloid-beta in Alzheimer's disease. Nature reviews. 2007, 8: 499-509. 10.1038/nrn2168.PubMedCrossRef

Pratico D: Alzheimer's disease and oxygen radicals: new insights. Biochemical pharmacology. 2002, 63: 563-567. 10.1016/S0006-2952(01)00919-4.PubMedCrossRef

Funderburk SF, Marcellino BK, Yue Z: Cell "self-eating" (autophagy) mechanism in Alzheimer's disease. Mt Sinai J Med. 2010, 77: 59-68. 10.1002/msj.20161.PubMedCrossRef

10.

Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences of the United States of America. 1985, 82: 4245-4249. 10.1073/pnas.82.12.4245.PubMedCrossRef

11.

Glenner GG, Wong CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and biophysical research communications. 1984, 120: 885-890. 10.1016/S0006-291X(84)80190-4.PubMedCrossRef

12.

Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (New York, NY). 2002, 297: 353-356.CrossRef

13.

Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al: Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature medicine. 1996, 2: 864-870. 10.1038/nm0896-864.PubMedCrossRef

14.

Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995, 375: 754-760. 10.1038/375754a0.PubMedCrossRef

15.

Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991, 349: 704-706. 10.1038/349704a0.PubMedCrossRef

16.

Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, Goate A, Rossor M, Roques P, Hardy J, et al: Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature. 1991, 353: 844-846. 10.1038/353844a0.PubMedCrossRef

17.

Glabe CC: Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. Sub-cellular biochemistry. 2005, 38: 167-177. full_text.PubMedCrossRef

18.

Klein WL: Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochemistry international. 2002, 41: 345-352. 10.1016/S0197-0186(02)00050-5.PubMedCrossRef

19.

Selkoe DJ: Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behavioural brain research. 2008, 192: 106-113. 10.1016/j.bbr.2008.02.016.PubMedCrossRef

20.

Kosik KS, Joachim CL, Selkoe DJ: Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 1986, 83: 4044-4048. 10.1073/pnas.83.11.4044.PubMedCrossRef

21.

Ihara Y, Nukina N, Miura R, Ogawara M: Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. Journal of biochemistry. 1986, 99: 1807-1810.PubMed

22.

Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI: Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences of the United States of America. 1986, 83: 4913-4917. 10.1073/pnas.83.13.4913.PubMedCrossRef

23.

Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A: Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proceedings of the National Academy of Sciences of the United States of America. 1988, 85: 4051-4055. 10.1073/pnas.85.11.4051.PubMedCrossRef

24.

Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM: Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem. 2006, 281: 39413-39423. 10.1074/jbc.M608485200.PubMedCrossRef

25.

Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E: Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging. 2003, 24: 1079-1085. 10.1016/j.neurobiolaging.2003.04.007.PubMedCrossRef

26.

Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, et al: Tau suppression in a neurodegenerative mouse model improves memory function. Science (New York, NY). 2005, 309: 476-481.CrossRef

27.

Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB: Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science (New York, NY). 2001, 293: 711-714.CrossRef

28.

Buratti E, Baralle FE: Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci. 2008, 13: 867-878. 10.2741/2727.PubMedCrossRef

29.

Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (New York, NY). 2006, 314: 130-133.CrossRef

30.

Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, Clark CM, Elman LB, Miller BL, Grossman M, et al: Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. The American journal of pathology. 2008, 173: 182-194. 10.2353/ajpath.2008.080003.PubMedCrossRef

31.

Caccamo A, Majumder S, Deng JJ, Bai Y, Thornton FB, Oddo S: Rapamycin rescues TDP-43 mislocalization and the associated low molecular weight neurofilament instability. J Biol Chem. 2009, 284: 27416-24. 10.1074/jbc.M109.031278.PubMedCrossRef

32.

Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, Xu Y, Neumann M, Trojanowski JQ, Lee VM: Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. J Biol Chem. 2009, 284: 8516-8524. 10.1074/jbc.M809462200.PubMedCrossRef

33.

Nonaka T, Kametani F, Arai T, Akiyama H, Hasegawa M: Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Human molecular genetics. 2009, 18: 3353-3364. 10.1093/hmg/ddp275.PubMedCrossRef

34.

Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW: TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Annals of neurology. 2007, 61: 435-445. 10.1002/ana.21154.PubMedCrossRef

35.

Bigio EH: TAR DNA-binding protein-43 in amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer disease. Acta neuropathologica. 2008, 116: 135-140. 10.1007/s00401-008-0405-z.PubMedCrossRef

36.

Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, Togo T, Katsuse O, Uchikado H, Furukawa Y, et al: Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain research. 2007, 1184: 284-294. 10.1016/j.brainres.2007.09.048.PubMedCrossRef

37.

Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, Miller BL, Kretzschmar HA, Lee VM, Trojanowski JQ, Neumann M: Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. Journal of neuropathology and experimental neurology. 2008, 67: 555-564. 10.1097/NEN.0b013e31817713b5.PubMedCrossRef

38.

Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM: Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003, 39: 409-421. 10.1016/S0896-6273(03)00434-3.PubMedCrossRef

39.

Hu WT, Josephs KA, Knopman DS, Boeve BF, Dickson DW, Petersen RC, Parisi JE: Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta neuropathologica. 2008, 116: 215-220. 10.1007/s00401-008-0400-4.PubMedCrossRef

40.

Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K: Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: Their relation to AD common pathology. Neuropathology. 2009, 5: 566-73. 10.1111/j.1440-1789.2009.01017.x.CrossRef

41.

Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM: Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging. 2003, 24: 1063-1070. 10.1016/j.neurobiolaging.2003.08.012.PubMedCrossRef

42.

Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM: Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J Neurochem. 2007, 102: 1053-1063. 10.1111/j.1471-4159.2007.04607.x.PubMedCrossRef

43.

Billings LM, Green KN, McGaugh JL, LaFerla FM: Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3×Tg-AD mice. J Neurosci. 2007, 27: 751-761. 10.1523/JNEUROSCI.4800-06.2007.PubMedCrossRef

44.

Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM: Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem. 2006, 281: 1599-1604. 10.1074/jbc.M507892200.PubMedCrossRef

45.

Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL: Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA. 2003, 100: 10417-10422. 10.1073/pnas.1834302100.PubMedCrossRef

46.

Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (New York, NY). 2003, 300: 486-489.CrossRef

47.

Oddo S, Caccamo A, Tseng B, Cheng D, Vasilevko V, Cribbs DH, LaFerla FM: Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci. 2008, 28: 12163-12175. 10.1523/JNEUROSCI.2464-08.2008.PubMedCrossRef

48.

Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, Iritani S, Onaya M, Akiyama H: Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta neuropathologica. 2009, 117: 125-136. 10.1007/s00401-008-0480-1.PubMedCrossRef

49.

Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH: Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005, 8: 79-84. 10.1038/nn1372.PubMedCrossRef

50.

Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG: Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 2005, 280: 17294-17300. 10.1074/jbc.M500997200.PubMedCrossRef

51.

Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG: Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem. 2004, 279: 46363-46366. 10.1074/jbc.C400260200.PubMedCrossRef

52.

Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ: Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005, 11: 556-561. 10.1038/nm1234.PubMedCrossRef

53.

Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, et al: Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998, 95: 6448-6453. 10.1073/pnas.95.11.6448.PubMedCrossRef

54.

Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002, 416: 535-539. 10.1038/416535a.PubMedCrossRef

55.

Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL: Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002, 924: 133-140. 10.1016/S0006-8993(01)03058-X.PubMedCrossRef

56.

Dickey CA, De Mesquita DD, Morgan D, Pennypacker KR: Induction of memory-associated immediate early genes by nerve growth factor in rat primary cortical neurons and differentiated mouse Neuro2A cells. Neuroscience letters. 2004, 366: 10-14. 10.1016/j.neulet.2004.04.089.PubMedCrossRef

57.

Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, Moolman D, Zhang H, Shelanski M, Arancio O: Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell. 2006, 126: 775-788. 10.1016/j.cell.2006.06.046.PubMedCrossRef

58.

Anderson AJ, Cummings BJ, Cotman CW: Increased immunoreactivity for Jun- and Fos-related proteins in Alzheimer's disease: association with pathology. Experimental neurology. 1994, 125: 286-295. 10.1006/exnr.1994.1031.PubMedCrossRef

59.

MacGibbon GA, Lawlor PA, Walton M, Sirimanne E, Faull RL, Synek B, Mee E, Connor B, Dragunow M: Expression of Fos, Jun, and Krox family proteins in Alzheimer's disease. Experimental neurology. 1997, 147: 316-332. 10.1006/exnr.1997.6600.PubMedCrossRef

60.

von der Kammer H, Demiralay C, Andresen B, Albrecht C, Mayhaus M, Nitsch RM: Regulation of gene expression by muscarinic acetylcholine receptors. Biochemical Society symposium. 2001, 131-140.

61.

Caccamo A, Majumder S, Richardson A, Strong R, Oddo S: Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem. 2010, 285: 13107-13120. 10.1074/jbc.M110.100420.PubMedCrossRef

62.

Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, Bailey R, Pickering-Brown S, Dickson D, Petrucelli L: Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci. 2007, 27: 10530-10534. 10.1523/JNEUROSCI.3421-07.2007.PubMedCrossRef

63.

Matsui T, Ramasamy K, Ingelsson M, Fukumoto H, Conrad C, Frosch MP, Irizarry MC, Yuan J, Hyman BT: Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels. Journal of neuropathology and experimental neurology. 2006, 65: 508-515. 10.1097/01.jnen.0000229238.05748.12.PubMedCrossRef

64.

Chong YH, Shin YJ, Lee EO, Kayed R, Glabe CG, Tenner AJ: ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem. 2006, 281: 20315-20325. 10.1074/jbc.M601016200.PubMedCrossRef

65.

Picone P, Carrotta R, Montana G, Nobile MR, San Biagio PL, Di Carlo M: Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. Biophysical journal. 2009, 96: 4200-4211. 10.1016/j.bpj.2008.11.056.PubMedCrossRef

66.

Resende R, Ferreiro E, Pereira C, Resende de Oliveira C: Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience. 2008, 155: 725-737. 10.1016/j.neuroscience.2008.06.036.PubMedCrossRef

67.

Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM: Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging. 2008, 29: 1607-1618. 10.1016/j.neurobiolaging.2007.04.014.PubMedCrossRef

68.

Zhang YJ, Gendron TF, Xu YF, Ko LW, Yen SH, Petrucelli L: Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragments. Mol Neurodegener. 2010, 5: 33-10.1186/1750-1326-5-33.PubMedCrossRef

69.

Wang X, Fan H, Ying Z, Li B, Wang H, Wang G: Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neuroscience letters. 2010, 469: 112-116. 10.1016/j.neulet.2009.11.055.PubMedCrossRef

70.

Urushitani M, Sato T, Bamba H, Hisa Y, Tooyama I: Synergistic effect between proteasome and autophagosome in the clearance of polyubiquitinated TDP-43. J Neurosci Res. 2010, 88: 784-797.PubMed

Title: Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to Aβ oligomers accumulation
Authors: Antonella Caccamo
Andrea Magrí
Salvatore Oddo
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Molecular Neurodegeneration / Issue 1/2010
Electronic ISSN: 1750-1326
DOI: https://doi.org/10.1186/1750-1326-5-51

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to Aβ oligomers accumulation

Abstract

Background

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Heat shock protein 90 in neurodegenerative diseases

Dynamic transport and localization of alpha-synuclein in primary hippocampal neurons

Retrieval of the Alzheimer's amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated

Identification of BACE1 cleavage sites in human voltage-gated sodium channel beta 2 subunit

Presenilin-1 regulates induction of hypoxia inducible factor-1α: altered activation by a mutation associated with familial Alzheimer's disease

Aberrant ERK 1/2 complex activation and localization in scrapie-infected GT1-1 cells